PGD2 receptor antagonists for the treatment of inflammatory diseases

a technology of pgd2 receptor and inflammatory diseases, which is applied in the field of prostagland, can solve the problems that clinicians will not be able to exploit the discovery of crth2 inhibitors, and few if any known crth2 inhibitors, and achieve the effect of inhibiting the binding of pgd2

Inactive Publication Date: 2006-05-18
MILLENNIUM PHARMA INC
View PDF15 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0003] It has now been found that certain 1,2,3,4-tetrahydro-quinolin-4-yl-amines are potent inhibitors of CRTH2. For example, many compounds effectively inhibited the binding of PGD2 to HEK-293 cells which stably express CRTH2...

Problems solved by technology

Unfortunately, there are few if any known CRTH2 inhibitors.
As a consequence, clinic...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PGD2 receptor antagonists for the treatment of inflammatory diseases
  • PGD2 receptor antagonists for the treatment of inflammatory diseases
  • PGD2 receptor antagonists for the treatment of inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The present invention is directed to inhibitors of the chemoattractant receptor-homologous molecule expressed on Th2 cells, also referred to herein as “CRTH2”. The prostaglandin PGD2 is a natural ligand for CRTH2, where it binds and induces at least some of its pro-inflammatory activity. Thus, the disclosed compounds can be used to inhibit CRTH2 activity; to inhibit PGD2 activity and to inhibit or treat (therapeutically or prophylactically) inflammatory disorders and allergic conditions mediated by CRTH2 and / or PGD2. Immune system cells which express CRTH2 include Th2 cells, eosinophils and basophils. Thus, the disclosed compounds can be advantageously used to inhibit inflammatory disorders and allergic conditions mediated by these cells.

[0025] In a first preferred embodiment of the present invention, X is —CHR2—, R2 is —H, methyl or ethyl; R3 is a substituted or unsubstituted aromatic group; R5 and R6 are —H; and the remainder of the variables in Structural Formula (I) are ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Electrical conductanceaaaaaaaaaa
Login to view more

Abstract

Disclosed herein are compounds represented by Structural Formula (I):
(I), wherein the variables are defined herein. Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 (“CRTH2”) for the treatment of inflammatory disorders.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 678,872, filed Oct. 3, 2003, which claims the benefit of U.S. Provisional Application No. 60 / 416,501, filed Oct. 4, 2002, now abandoned. Each of these applications is hereby incorporated in its entirety by reference herein.BACKGROUND OF THE INVENTION [0002] PGD2 belongs to the class of prostaglandins derived from arachidonic acid. It is the predominant prostanoid produced by activated mast cells and is involved in the pathogenesis of allergic diseases such as asthma, rhinitis and atopic dermatitis (see Lewis et al. J. Immunol. 129:1627 (1982), Hardy et al., N. Eng. J. Med. 311: 209 (1984), Murray et al., N. Eng. J. Med. 315: 800 (1986), Barry et al., Br. J. Pharmacol. 94:773 (1988). PGD2 is a ligand for the DP receptor and was initially thought to elicit all its biological actions through this receptor. The role of the DP receptor in allergic asthma has been demon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D215/36C07D215/38A61K31/4706A61K31/4353A61K31/47C07D215/42C07D215/44C07D401/06C07D401/10C07D401/12C07D405/06C07D409/06C07D413/06C07D413/10C07D417/06C07D471/04C07D491/04C07D495/04
CPCA61K31/4353A61K31/47C07D215/42C07D215/44C07D401/06C07D401/10C07D401/12C07D405/06C07D409/06C07D413/06C07D413/10C07D417/06C07D471/04C07D491/04C07D495/04Y02P20/582A61P1/04A61P1/16A61P1/18A61P11/00A61P11/02A61P11/06A61P13/12A61P15/00A61P15/02A61P17/00A61P17/02A61P17/04A61P17/06A61P17/10A61P19/02A61P19/04A61P19/08A61P21/00A61P21/04A61P25/00A61P27/16A61P29/00A61P35/00A61P37/02A61P37/06A61P37/08A61P43/00A61P5/14A61P9/00A61P9/10A61P3/10C07D215/50
Inventor GHOSH, SHOMIRELDER, AMYCARSON, KENNETHSPROTT, KEVINHARRISON, SEAN
Owner MILLENNIUM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap